FDA approves Pfizer and Moderna booster doses, authorizes mix and match for COVID-19 vaccines
Author
Blaire Bryant
Upcoming Events
Related News
Key Takeaways
On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP). The endorsement follows the Food and Drug Administration’s (FDA) October 20 announcement approving the emergency use of booster doses for both vaccines.
The CDC also endorsed the use of heterologous (mix and match) COVID-19 vaccine booster shots, following FDA approval based on safety and efficacy data. Eligible individuals will be able to select their booster dose from any of the FDA endorsed or approved COVID-19 vaccines.
Updated guidelines for the use of a COVID-19 vaccine booster dose are as follows:
- Johnson & Johnson COVID-19 vaccine: A single booster dose may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.
- Moderna COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals that are 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, or 18 through 64 years of age with frequent institutional or occupational exposure to COVID-19.
- Pfizer-BioNTech COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.
As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 190 million vaccinations in the U.S. to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 boosters, see the “Vaccine Booster Readiness Checklist for County Health Facilities” tab in NACo’s COVID-19 Vaccine Distribution Toolkit.
ADDITIONAL RESOURCES
Resource
COVID-19 Vaccine Toolkit for Counties
Related News
Congress introduces legislation to restore critical public health funding
On November 14, the Public Health Funding Restoration Act (H. R. 10126/S. 5326) was introduced in both the U.S. Senate and House of Representatives. This legislation would address a pressing need to strengthen the nation’s public health infrastructure through direct and flexible funding to local health entities. By restoring critical funding to the Prevention and Public Health Fund (PPHF), the bill aims to equip communities with the tools needed to tackle modern public health challenges, from chronic disease prevention to emergency response.
CMS finalizes Medicare rule with key improvements for justice-involved populations
On November 1, the Centers for Medicare & Medicaid Services (CMS) published a final rule that, in a major advocacy win for counties, will improving access to Medicare for justice-involved individuals who are in pre-trial status or who are reentering the community. The CY 2025 Medicare Hospital Outpatient Prospective Payment System final rule reflects significant updates to Medicare’s “custody” definition and Special Enrollment Period (SEP) for formerly incarcerated individuals.
Six years of the SUPPORT Act: Ongoing behavioral health policy priorities for counties
On October 24, 2018, the bipartisan SUPPORT Act was enacted. It represented the largest Congressional investment in overdose prevention at the time, aiming to strengthen the nation's response to the substance use crisis.